drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T; BCMA-directed)
drug_description
Autologous BCMA-directed CAR T-cell therapy; engineered T cells target and kill BCMA-positive malignant plasma cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Ciltacabtagene Autoleucel
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered with a BCMA-directed chimeric antigen receptor recognize BCMA on malignant plasma cells and, upon antigen engagement, activate T‑cell cytotoxicity (perforin/granzyme release and cytokine signaling) to kill BCMA‑positive cells and mediate tumor clearance.
drug_name
Ciltacabtagene autoleucel (cilta-cel)
nct_id_drug_ref
NCT05257083